Malignant brain tumors, also called brain cancer, are the second leading cause of cancer deaths among children and young adults. The causes of brain tumors are currently unknown. They are likely to grow rapidly and invade the nearby normal brain. Cancer cells can break away and spread to ...
Every patient should be assessed individually in order to evaluate her health status, including her overall health, the primary cancer, the treatment received and the possible side effects of the treatment. Pregnancy after breast cancer is especially challenging because of the hormonal influence on the...
Even when treated with surgery, radiation, and chemotherapy, the median life expectancy of brain cancer patients is only 12-14 months [5, 6]. Despite significant gains in the understanding of glioblastoma biology, the prognosis of the disease has not significantly changed over the last 20 years...
Brain metastases (BM) is a common complication, especially with advanced-stage melanoma. Melanoma accounts for almost 10 percent of BM and the third leading cause after lung and breast cancer.[11]In a large multi-institutional adjuvant study, the incidence of BM is about 15 percent in...
Nakagawa Y, Hirakawa K, Ueda S (1983) Local administration of interferon for malignant brain tumors. Cancer Tret Rep 67:833–855 Oda Y, Konishi T, Suzui H et al. (1989) Efficacy and adverse effects of beta interferon in the treatment of malignant gliomas. Nippon Gan Chiryo Gakkai Shi...
HCC, hepatocellular carcinoma; PDAC, pancreatic ductal adenocarcinoma, TC, thyroid cancer, GBM BITC, glioblastoma brain tumor–initiating cell; TNBC, triple-negative breast cancer. Table 1. Preclinical studies of PD-1 antibodies-based combination therapy for tumors. Tumor typesCombined therapyEffectRef....
Conclusion For mobility preservation, one 10-Gy fraction is non-inferior to 20 Gy in five fractions, in patients with MSCC not proceeding with surgical decompression. Clinical Trial Registration Cancer Trials Ireland ICORG 05-03; NCT00968643; EU-20952.Similar...
To date ACC remains a subtype of salivary gland cancer in which advancement of clinical outcome has been elusive. Chief among these obstacles for managing this cancer is the high rate of local and distant tumor progression. These clinical features in combination with the high incidence of cKIT ...
North Central Cancer Treatment Group (NCCTG) conducted a Phase II trial of vorinostat, a small-molecule inhibitor of human HDAC1, 2, 3, 6 and 8 that crosses the blood-brain barrier, in 66 patients with recurrent glioblastoma (Galanis et al., 2009). The agent was administered at a dose ...
However, in cancer cells the connection between SCD1 expression and malignancy (patients' shorter life expectancy) has been assigned [28] and Igal clarified all the reported data on the FA levels and SCD1. The objective of this study was to detect and compare FA composition, assess the ...